Highlights

FURENPOL

Enzymatic synthesis and recycling of bio-based furanic polymers.

CSO Job Offer

NBD is seeking an experienced scientist in the area of computational drug discovery to become the CSO with the mission of collaborating in the definition of the scientific strategy of the company in order to produce IP by using the NBD Suite and plan the new necessary software developments

Computer simulations to aid rational enzyme engineering

Enzymes are highly selective biological catalysts that enable virtually all chemical reactions in life. Despite their vast potential, industrial applications might be restricted to several catalytic features, since these biocatalysts have evolved to function optimally under biological conditions.

Elucidating allosteric regulations by means of computer simulations

Combining coevolutionary information, molecular simulations and free-energy methods to elucidate and quantify allosteric regulation.

PELE Platform 1.6 is here

PELE Platform is a suite of packages that aims to find novel solutions to drug discovery problems in a matter of hours... And we just released a new version!

Bioactivity descriptors for uncharacterized chemical compounds

The SBNB group at IRB has been working on a deep neural networks methodology to infer bioactivity signatures of small molecule ligands with little experimental data available.

Exciting news: AlphaFold code released

Predicting protein structures based solely on amino acid sequences has been the holy grail of biology for decades. Learn how AlphaFold changed the field.

Impact of DNA methylation on the 3D structure of the genome

Our co-founder Prof. Modesto Orozco has led a study that demonstrates that DNA methylations intrinsically modulate genome structure and function by increasing its overall rigidity.

State-of-the-art enzyme engineering by structure-based modelling techniques

Enzymatic processes are key to providing biotechnological solutions in the immediate future of our society, tackling clean energy production, bioremediation...

Why it’s important to get the right lead molecule

The success of a new drug campaign is highly dependent on the selection of lead series very early on in the drug discovery process. Find out how we can help!

Emerging trends: Covalent inhibitors

With over 50 approved drugs currently on the market, covalent inhibitors seem to be a hot topic! Find out what all the fuss is about and we’re doing to stay on top of things.

Javier Iglesias appointed as the new leader of the Enzyme Engineering division

Dr. Iglesias, who recently joined NBD as Project Manager for the Nucleic Acids Division, has been internally promoted to substitute the...